Sarclisa Archives -

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new

Blackstone funds new trials of Sanofi’s Sarclisa in myeloma

https://pharmaphorum.com/news/blackstone-funds-new-trials-of-sanofis-sarclisa-in-myeloma/

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma,

Sanofi’s Sarclisa gains new US multiple myeloma indication

https://pharmaphorum.com/news/sanofis-sarclisa-gains-new-us-multiple-myeloma-indication/

Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

https://pharmaphorum.com/news/sanofi-to-develop/

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

https://pharmaphorum.com/news/sanofi-builds-case-for-sarclisa-challenging-jjs-darzalex/

Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming

Sanofi gets first OK for isatuximab for myeloma, challenging J&J’s Darzalex

https://pharmaphorum.com/news/sanofi-gets-first-ok-for-isatuximab-for-myeloma-challenging-jjs-darzalex/

Sarclisa